Archive for May, 2008

Revolutionary plastic surgery videos helping patients

OlehManhattan-based facial plastic surgeon, Oleh Slupchynskyj, has developed breakthrough educational videos for YouTube, which are paving the way for how the medical community can inform consumers about plastic surgery do’s and don’ts, risks and benefits. Created initially for patients who wanted to learn all aspects of and watch firsthand the most popular plastic surgery procedures before choosing to undergo treatment themselves, each video has received the highest of ratings since just being posted on YouTube. The videos include live surgery footage, patient testimonials plus before-and-after photos for facelift surgery, rhinoplasty or nose surgery, and lip augmentation.

XenaCare Holdings launches UV sun defense pill

SunPillXenaCare Holdings Inc. has officially launched its new product called the SunPill® after an 8-month development program. The SunPill® is a dietary supplement that helps the skin protects itself from the harmful rays of the sun. The proprietary combination of ingredients with powerful antioxidant properties in the product helps the body’s own natural defense when it comes to exposure to the sun.

Take cosmetic injectables only when prescribed

InjectablesThe Physicians Coalition for Injectable Safety has issued a warning against the growing popularity of cosmetic injectables being offered as prizes or gifts. The Coalition leader, Renato Saltz, MD, of Salt Lake City, Utah, says that these injectables are medical treatments and should be taken only if prescribed by a physician.

ZymoGenetics presents positive results on RECOTHROM Thrombin

RecothromRecothromZymoGenetics Inc. has presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM™ Thrombin, a topical (Recombinant) administered by spray device to burn wound excision sites. The study revealed that the topical application of RECOTHROM using a pump spray device was well tolerated and it demonstrated a similar safety profile and rate of antibody formation to that observed in the rThrombin Phase 3 clinical trial.